Type 2 diabetes control
DOI: Observational studies have shown that both phylloquinone and menaquinone intake might reduce cardiovascular disease CVD risk. However, the effect of vitamin K on vascular calcification is unknown.
Objectives: The aim of this study was to assess if menaquinone supplementation, compared to placebo, decreases vascular calcification in people with type 2 diabetes and known CVD. Femoral arterial calcification at baseline and 6 mo was measured with 18sodium fluoride positron emission tomography 18F-NaF PET scans as target-to-background ratios TBRsa promising technique to detect active calcification.
Calcification mass on conventional computed tomography CT scan was measured as secondary outcome.
Dephosphorylated-uncarboxylated matrix Gla protein dp-ucMGP concentrations were measured to assess compliance. Linear regression analyses were performed with either TBR or CT calcification at follow-up as type 2 diabetes control dependent variable, and treatment and baseline TBR or CT calcification as independent variables.
Results: We randomly assigned 35 patients to the MK-7 group 33 completed follow-up and 33 to the placebo group 27 completed follow-up. Log-transformed CT calcification mass did not increase in the intervention group compared with placebo 0. MK-7 supplementation significantly reduced dp-ucMGP compared with placebo No adverse events were reported.
This trial was registered at clinicaltrials. Keywords: cardiovascular disease; diabetes; menaquinone-7; vascular calcification; vitamin K. Copyright © American Society for Nutrition Publication types.